Quick Answer
Oncotelic Therapeutics, Inc. reported Research And Development Expense of $61.1 thousand for the year ending 2023.
- Oncotelic Therapeutics, Inc. showed a decrease of -91.9% in Research And Development Expense from 2022 to 2023.
- This data is from Oncotelic Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 12, 2024.
- XBRL data for this metric is available from 2009 to 2023 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2009 to 2023), Oncotelic Therapeutics, Inc.'s Research And Development Expense has declined by 99.7%.
- Historical annual values: Fiscal year 2023: $61.1 thousand | Fiscal year 2022: $756.9 thousand | Fiscal year 2021: $3.66 million | Fiscal year 2020: $4.30 million | Fiscal year 2019: $1.37 million | Fiscal year 2018: $649.8 thousand | Fiscal year 2017: $10.47 million | Fiscal year 2016: $8.76 million | Fiscal year 2015: $9.09 million | Fiscal year 2014: $7.41 million | Fiscal year 2013: $3.64 million | Fiscal year 2012: $3.52 million | Fiscal year 2011: $5.29 million | Fiscal year 2010: $12.11 million | Fiscal year 2009: $22.26 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: